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Abstract
Background: Afghanistan's national guidelines recommend chloroquine for the treatment of Plasmodium vivax 
infection, the parasite responsible for the majority of its malaria burden. Chloroquine resistance in P. vivax is emerging in 
Asia. Therapeutic responses across Afghanistan have not been evaluated in detail.
Methods: Between July 2007 and February 2009, an open-label, randomized controlled trial of chloroquine and 
dihydroartemisinin-piperaquine in patients aged three months and over with slide-confirmed P. vivax mono-infections 
was conducted. Consistent with current national guidelines, primaquine was not administered. Subjects were followed 
up daily during the acute phase of illness (days 0-3) and weekly until day 56. The primary endpoint was the overall 
cumulative parasitological failure rate at day 56 after the start of treatment, with the hypothesis being that 
dihydroartemisinin-piperaquine was non-inferior compared to chloroquine (Δ = 5% difference in proportion of 
failures).
Results: Of 2,182 individuals with positive blood films for P. vivax, 536 were enrolled in the trial. The day 28 cure rate was 
100% in both treatment groups. Parasite clearance was more rapid with dihydroartemisinin-piperaquine than 
chloroquine. At day 56, there were more recurrent infections in the chloroquine arm (8.9%, 95% CI 6.0-13.1%) than the 
dihydroartemisinin-piperaquine arm (2.8%, 95% CI 1.4-5.8%), a difference in cumulative recurrence rate of 6.1% (2-sided 
90%CI +2.6 to +9.7%). The log-rank test comparing the survival curves confirmed the superiority of dihydroartemisinin-
piperaquine over chloroquine (p = 0.003). Multivariate analysis showed that a lower initial haemoglobin concentration 
was also independently associated with recurrence. Both regimens were well tolerated and no serious adverse events 
were reported.
Conclusions: Chloroquine remains an efficacious treatment for the treatment of vivax malaria in Afghanistan. In a 
setting where radical therapy cannot be administered, dihydroartemisinin-piperaquine provides additional benefit in 
terms of post-treatment prophylaxis, reducing the incidence of recurrence from 4-8 weeks after treatment.
Trial Registration: The trial was registered at ClinicalTrials.gov under identifier NCT00682578.
Background
Plasmodium vivax is associated with less mortality than
Plasmodium falciparum, but still exerts a considerable
burden of disease globally [1] and is a major cause of
morbidity in Asia [2]. In endemic areas it is a particular
problem of children and pregnant women in whom it is
associated with poor outcomes, notably anaemia and low
birth weight [3]. Control measures are confounded by the
persistence of dormant hypnozoite stages in the liver,
which cause relapses of the infection if radical therapy is
not administered. Chloroquine remains the treatment of
choice for treatment for the erythrocytic stage of P. vivax
infection, but chloroquine resistance is spreading [4].
High level resistance is still confined mainly to Oceania
[5] and Indonesia [6], but lower level resistance has been
reported in other areas across Asia and South America
[4].
* Correspondence: nickwdt@tropmedres.ac
1 Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
Full list of author information is available at the end of the articleAwab et al. Malaria Journal 2010, 9:105
http://www.malariajournal.com/content/9/1/105
Page 2 of 10
Chloroquine was used for more than 50 years as the
first-line drug for all forms of malaria in Afghanistan.
Chloroquine continues to be first-line drug treatment as a
mono-therapy for slide-confirmed P. vivax malaria and is
also used in combination with sulphadoxine-
pyrimethamine for presumptive treatment of clinical
malaria episodes when accurate laboratory diagnosis is
unavailable. Radical treatment with primaquine is not
currently recommended because of the risk of oxidant
haemolysis in patients with glucose-6-phosphate dehy-
drogenase (G6PD) deficiency, as testing for G6PD defi-
c i e n c y  i s  n o t  a v a i l a b l e .  L i m i t e d  a c c e s s  t o  p r o m p t
diagnosis and treatment, self-medication with low quality
medicines [7] and non-adherence to the national treat-
ment policy are all potential contributors to drug resis-
tance in Afghanistan. To date, anti-malarial therapeutic
monitoring in Afghanistan has largely been conducted at
the Malaria Reference Centre, Jalalabad (Nangarhar prov-
ince) in the eastern region of the country near the border
with Pakistan. In this area, chloroquine resistance is
established in P. falciparum [8] but appears not to be a
major problem for P. vivax [9,10]. Relatively little data
exists for the rest of the country; sulphadoxine-
pyrimethamine has been shown to have good efficacy
against P. falciparum in Kunduz province [11] and molec-
ular studies indicate that P. vivax resistance to sulphadox-
ine-pyrimethamine is present at a relatively early stage in
Nangarhar and Herat provinces[12].
Since 2004, artemisinin combination therapy (ACT) in
the form of artesunate/sulphadoxine-pyrimethamine has
been the recommended first-line treatment for P. falci-
parum infections in Afghanistan. As the correct malaria
parasite species may not be identified in patients present-
ing with fever, P. vivax infections in Afghanistan will inev-
itably be treated with ACT [9]. For operational reasons,
there may an argument for treating both vivax and falci-
parum malaria with the same drug regimen. The fixed-
dose combination of dihydroartemisinin co-formulated
with the bisquinoline piperaquine represents a promising
alternative to chloroquine. Piperaquine is related to 4-
aminoquinolines but it retains activity against chloro-
quine-resistant  P. falciparum [13] and several studies
from Indonesia and Papua New Guinea have indicated
that dihydroartemisinin-piperaquine is also safe and
effective for the treatment of chloroquine-resistant vivax
malaria, with more long-lasting post-treatment prophy-
lactic effects than other forms of ACT [5,14,15]. Dihy-
droartemisinin-piperaquine is relatively expensive (1-2
US$ per treatment course) but has a simple dosing sched-
ule (daily doses for three days).
For the purpose of evidence-based decision making,
and to obtain better information on the effectiveness of
available anti-malarial drugs against vivax malaria in
Afghanistan, the relative therapeutic efficacy of chloro-
quine and dihydroartemisinin-piperaquine in the treat-
ment of vivax malaria was assessed at three sites in
Afghanistan.
Methods
Study area and participants
The study was conducted from July 2007 to February
2009 at three provincial malaria control centres, one in
the east and two in the north of the country. The epide-
miology of malaria in Afghanistan is determined by the
physical geography of the country, malaria being con-
fined to lower lying areas with sufficient rainfall for mos-
quito survival consisting of the northern plains
(bordering Turkmenistan, Uzbekistan and Tajikistan)
[16], the Jalalabad basin to the east (bordering Pakistan)
and river valleys that fringe the central mountains to the
west and south [17]. The central area of Afghanistan,
occupied by the western end of the Hindu Kush moun-
tain range, is relatively free of malaria [18,19]. In Afghani-
stan, P. vivax remains endemic and accounts for more
than 90% of all malaria cases [20]. Cases begin to present
in the spring months (May onwards) consistent with peri-
odic relapse from long latency hypnozoites, reach a peak
in July and August, and few cases are seen after Novem-
ber.
Jalalabad, capital of Nangarhar province, is a referral
centre for the whole eastern region and lies adjacent to
the Pakistani border where population movement in both
directions takes place. The population is multi-ethnic
with Pashtoon being the dominant group. The province
as a whole (altitudes below 2,000 meters) is generally
semiarid but where possible rice is cultivated. Taloqan is
the capital of the north-east province of Takhar with a
population that is mainly Tajik with significant propor-
tions of Uzbek and Pashtoon. Rice is cultivated on the
plain and malaria is a well-known health problem [21].
Maimana is the capital city of the north-west province of
Faryab bordering Turkmenistan, with which there is no
open border. The population is mainly Uzbek and Turk-
men and the region is semi-arid.
Enrolment
This was a prospective, open label, randomized con-
trolled trial conducted in patients with microscopically
confirmed symptomatic vivax malaria who were aged
three months and older. All febrile patients over three
months of age presenting to the sites were screened and
enrolled according to preset criteria. A standard data
sheet was used to record demographic information,
details of symptoms and their duration, and previous
anti-malarial medications. Clinical examination findings
and vital signs were documented, including axillary tem-
perature measured with a digital thermometer. Venous
blood samples were obtained for haemoglobin measure-Awab et al. Malaria Journal 2010, 9:105
http://www.malariajournal.com/content/9/1/105
Page 3 of 10
ment (Hemocue) and white cell count using the counting
chamber method. Giemsa-staining of thick and thin
blood films was performed to confirm parasite species
and parasitaemia by a standard approximation method
(40 × number of parasites per 200 white blood cells on
the thick film). 10% of slides were cross-checked in the
MORU (Bangkok) parasitology laboratory. Approxi-
mately 20 μl capillary blood was collected on filter papers
for subsequent confirmation of species by PCR and
future molecular studies. Slide examination results were
considered to be negative after examination of 30 high-
power fields of the thick film.
The inclusion criteria were slide-confirmed infection
with asexual stages of P. vivax, written informed consent
by the patient or attending parent/guardian, and a nega-
tive urine pregnancy test in women of childbearing age.
Exclusion criteria were any clinical or laboratory feature
of severe malaria [22], haemoglobin concentration of less
than 7 g/dl, concomitant disease that would mask treat-
ment responses, known allergy to any of the study drugs,
anti-malarial treatment in the previous month, mixed
species Plasmodium infection, pregnancy (or unwilling-
ness to undergo pregnancy testing), lactation, and antici-
pated inability or unwillingness to complete the 56 day
follow-up.
Randomization
Patients were allocated to the two treatment arms based
on a pre-generated randomization list made in blocks of
20 that was produced and held independently of the field
teams by a statistician. The individual allocations were
kept in sealed, opaque envelopes and opened only after
enrolment by the field team. Patients and clinical field
workers were, therefore, not blinded to the treatment arm
after allocation. Microscopists were blinded to treatment
allocation at follow-up examinations.
Drugs
Patients received either quality-controlled chloroquine
(IDA, Netherlands) aiming for a target total dose of 25
mg base/kg in divided doses over three days, or dihy-
droartemisinin-piperaquine (Artekin®, each tablet con-
taining 40 mg dihydroartemisinin and 320 mg
piperaquine; Holleypharm, China) aiming for a target
total dose of 6/48 mg/kg in divided doses over three days.
According to the body weight, individual doses were
either rounded to the nearest half or quarter tablet or, if
necessary, tablets were crushed, mixed with 5 ml water
and the appropriate volume was given. All doses were
taken under supervision at the malaria treatment centre
and patients were observed for 60 minutes after drug
administration. Patients vomiting within this time
received the same dose again. Patients who vomited the
medication twice were withdrawn from the study.
Follow-up
The subjects were seen on days 0 to 3 inclusive and
weekly to 56 days, so that late recrudescence and relapses
could be detected [23,24]. Patients were also requested to
attend if they felt unwell on any other day during the 56
days of follow-up. At each follow up visit a clinical assess-
ment was undertaken and the patient was asked about
adverse events by the use of a standard symptom ques-
tionnaire. Thick and thin blood slides were examined and
haemoglobin was measured. Other tests such as periph-
eral white blood cell count and urine examination were
undertaken as indicated to rule out other conditions and
investigate possible adverse effects of drugs. Patients
showing parasitological failure with recurrence of P. vivax
had capillary blood collected on filter paper for PCR anal-
ysis and were treated with chloroquine (25 mg base/kg
over 3 days) and followed up by standard protocols.
Patients with mixed P. falciparum/P. vivax infection were
also classified as treatment failures but treated with arte-
sunate/sulphadoxine-pyrimethamine. Patients were cen-
sored from the analysis if there was stated withdrawal of
consent at any stage, persistent vomiting during the acute
phase (necessitating parenteral treatment) or occurrence
during the follow-up of concomitant disease that would
interfere with a clear classification of the treatment out-
come (including mono-infection with P. falciparum).
Patients failing to attend follow-up visits received a visit
at home and were asked to reattend the centre for assess-
ment. Transportation was provided for all follow-up vis-
its for all subjects. All enrolled patients were given one
long-lasting insecticide treated bed net.
Outcomes
The primary outcome was the difference in the propor-
tion of patients with parasitologically-confirmed recur-
rence of P. vivax infection at or before day 56 between the
two arms. Secondary outcomes were parasite and fever
clearance times, recurrence at earlier time points, game-
tocytaemia at day 28 and 56, haemoglobin recovery, and
safety and tolerability of the treatments.
Sample size
Given the relatively high predicted efficacy of chloro-
quine, a non-inferiority design was used [23] with the aim
of testing whether dihydroartemisinin-piperaquine was
non-inferior to (i.e. equivalent or better than) chloro-
quine in terms of the proportion of patients with parasi-
tological failure at 56 days; the non-inferiority margin (Δ)
was set at 5%. The sample size was 550 patients (275 per
arm), calculated assuming a 95% cure rate with chloro-
quine, a one-sided alpha of 0.05 and 80% power.
Statistical analysis
Data were double entered into Microsoft Access. All
analyses were conducted using STATA version 9.0. TheAwab et al. Malaria Journal 2010, 9:105
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Student's t-test, Mann-Whitney U and chi-squared (or
Fisher's exact) tests were used for comparison of baseline
variables, as appropriate. Parasitological failure rates
were assessed by survival analysis using the Kaplan-Meier
method and Wilson confidence intervals for the differ-
ence in efficacy proportions were calculated using the
effective sample size [25]. Dihydroartemisinin-piper-
aquine was considered non-inferior to chloroquine if the
lower bound of the confidence interval of the difference
was greater than 0.05 (the non-inferiority margin). Differ-
ences between treatment groups were estimated using
the log-rank test. A sensitivity analysis, in which losses to
follow-up were considered failures, was also undertaken
[26]; patients who did not complete treatment were
excluded. Cox regression including age (years), gender,
recruitment site, treatment arm, admission haemoglobin
level (g/dl), presence of gametocytes and parasitaemia as
independent variables was performed to identify possible
independent predictors of recurrence, using a stepwise
elimination method.
Species confirmation by PCR
DNA was extracted from filter-paper blood spots and
nested PCR performed to detect P. vivax and  P. falci-
parum as described previously [27].
Ethical approval
The study was approved by the Ethics Committee of the
Faculty of Tropical Medicine, Mahidol University, Thai-
land, the Oxford Tropical Research Ethics Committee,
Oxford University, UK and the Institutional Review
Board of the Afghan Public Health Institute, Ministry of
Public Health, Afghanistan. The trial was registered with
the clinical trials website http://www.clinicaltrials.gov/ct
as NCT00682578. This description of the trial describes
recruitment of patients with uncomplicated infection
with either P. falciparum or  P. vivax, with treatments
depending on the species detected. Recruitment of P. fal-
ciparum cases proved much slower than for P. vivax and
the ongoing P. falciparum study will be presented else-
where.
Results
Recruitment
From July 2007 to February 2009, 536 patients were
enrolled in the study with 268 receiving chloroquine and
268 dihydroartemisinin-piperaquine (Figure 1). The main
reasons for not being enrolled in the study were lack of
consent (n = 608; 37%), history of taking anti-malarial
drugs in the past month (n = 394; 24%), home too far
away for follow-up (n = 337; 20%), concomitant disease (n
= 228; 14%), pregnancy or lactation (n = 113; 7%), mixed
infection with P. falciparum (n = 44) and severe malaria
(n = 12). The majority of patients (314/536 (58.6%)) were
recruited in Jalalabad; 119 (22.2%) patients were recruited
in Taloqan and 103 (19.2%) in Maimana. 73 (13.6%)
patients were less than five years of age, 258 (48.1%) were
5-14 years of age and 205 (38.2%) were 15 or older.
At the reference laboratory 94% of baseline slides were
confirmed as P. vivax monoinfection; the remaining
slides were classed as Plasmodium infection of undeter-
mined species because of slide quality. PCR confirmation
was undertaken on an independent, randomly selected
subset of paired blood samples from 10 patients with par-
asitological failure. All 10 baseline samples and 9 of 10
samples taken at recurrence contained P. vivax by this
method. P. falciparum was not detected in any sample by
either microscopic or molecular methods.
Baseline characteristics
Patient characteristics at baseline were broadly similar
between the two treatment groups (Table 1) except that
the median white blood cell count was lower in the chlo-
roquine group compared with dihydroartemisinin-piper-
aquine (median 6.0 vs. 6.6 × 109/l respectively, p = 0.02).
Response to treatment and follow-up
Patients in the chloroquine group who completed treat-
ment received a median total dose of 25.9 mg/kg base
(IQR 25.0 - 27.3 mg/kg); for the dihydroartemisinin-pip-
eraquine group the median total dihydroartemisinin dose
was 6.0 mg/kg (IQR 5.45 - 6.67 mg/kg). Both treatments
were generally well tolerated. Repeated vomiting of the
study medication was not reported within 60 minutes of
drug administration in any patient. No patient deterio-
rated or developed signs of severity. Five patients who
received the first dose withdrew consent before complet-
ing treatment and were censored from analysis. Of the
531 individuals who completed treatment, 38 (7.2%) cases
were lost to follow-up before day 56; 13 in the chloro-
quine arm and 25 in dihydroartemisinin-piperaquine arm
(p = 0.04) (Figure 1).
Parasitological failures
By the end of the 56-day follow-up period, there were 23
recurrences (parasitological failures) in the chloroquine
group and 7 in the dihydroartemisinin-piperaquine
group, giving a day 56 failure rate of 8.9% (95% CI 6.0 -
13.1%) in the chloroquine group and 2.8% (1.4 - 5.8%) in
the dihydroartemisinin-piperaquine group (Figure 2).
The difference in day 56 parasitological failure rates
between chloroquine and dihydroartemisinin-piper-
aquine was 6.1% (2-sided 90% CI +2.6 to +9.7%). The
lower bound of this confidence interval was not only
higher than the prespecified non-inferiority margin (i.e. -
5%), but also did not include zero, indicating that dihy-
droartemisinin-piperaquine was superior to chloroquine
in terms of outcome (Figure 3) [26]. The superiority ofAwab et al. Malaria Journal 2010, 9:105
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dihydroartemisinin-piperaquine was confirmed by the
log rank test (p = 0.003).
A sensitivity analysis (in which all losses to follow-up
were classed as failures) yielded a difference in cumula-
tive parasitological failure rate between chloroquine and
dihydroartemisinin-piperaquine of 1.5% (2-sided 90% CI
-3.3 to +6.3%); as predicted there was a wider 90% confi-
dence interval than that based on survival analysis but
also a lower point estimate for the difference in failure
rate between the chloroquine and dihydroartemisinin-
piperaquine groups caused by the greater number of
losses to follow-up in the dihydroartemisinin-piper-
aquine group. The lower bound of the 90% confidence
interval was still higher than the prespecified non-inferi-
ority margin (5%), but included zero, indicating that dihy-
droartemisinin-piperaquine was not inferior to
chloroquine even in this considerably more conservative
analysis [26] (Figure 3).
Secondary outcomes
Initial parasitological responses were faster with dihy-
droartemisinin-piperaquine (Figure 4); in the dihydroar-
temisinin-piperaquine group 241/264 (91.3%) of patients
cleared their parasitaemia at day 1 compared to 209/265
(78.9%) in the chloroquine group (p < 0.001, relative risk
of clearance in chloroquine group = 0.87, 95% CI 0.81-
0.93). At day 2, the groups were no longer significantly
different with 259/265 (97.8%) of the dihydroartemisinin-
piperaquine group and 257/265 (97.0%) in the chloro-
quine group having cleared their parasitaemia (p = 0.59).
Two patients in the chloroquine arm remained parasitae-
mic at day 3.
In terms of resolution of fever (defined as axillary tem-
perature >37.0°C) dihydroartemisinin-piperaquine was
again superior (Figure 4), with 29/266 (10.9%) of the dihy-
droartemisinin-piperaquine group febrile on day 1 com-
pared to 45/268 (16.8%) in the chloroquine group (p =
0.049). By day 2 there was no longer a significant differ-
ence in the proportion with fever (3/265 (1.1%) for dihy-
droartemisinin-piperaquine, 9/264 (3.4%) for
chloroquine, p = 0.08). At day 1, headache was less fre-
quent in the dihydroartemisinin-piperaquine arm (105/
265 (39.6%)) compared to the chloroquine arm (145/266
(54.5%), p = 0.001).
The day 28 cure rate was 100% in both arms with the
first recurrences observed at day 35 in the chloroquine
group and day 42 in the dihydroartemisinin-piperaquine
group. Twenty-one of 30 (70%) recurrent parasitaemias
were associated with gametocytaemia, with no significant
difference between treatment arms in terms of propor-
Figure 1 Trial flow.
P. vivax positive cases 
assessed for eligibility 
(n=2172)
536 cases randomised
Excluded (n=1636)
Refusal of consent (n=608)
Prior history of antimalarial use (n=394)
Anticipated difficulty with follow-up (n=337)
Concomitant disease (n=228)
Pregnancy or lactation (n=113)
Mixed infection (n=44)
Signs of severity (n=12)
Allocated to CQ (n=268)
Received all CQ doses (n=266)
Did not complete CQ (n=2)
Lost to follow-up before d56 (n=13)
Completed to d56 without failure (n=230)
Failed on or before d56 (n=23)
Allocated to DP (n=268)
Received all DP doses (n=265)
Did not complete DP (n=3)
Lost to follow-up before d56 (n=25)
Completed to d56 without failure (n=233)
Failed on or before d56 (n=7)Awab et al. Malaria Journal 2010, 9:105
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tion of recurrent patients with gametocytaemia (16/23
and 5/7 for chloroquine and dihydroartemisinin-piper-
aquine respectively, p = 1.0).
Adverse events
There were no serious adverse events recorded during
the trial and no patient required hospitalization. Both
study drugs appeared to be well tolerated. There was a
significant increase in the proportion of patients with
pruritus in the chloroquine arm compared to dihydroar-
temisinin-piperaquine on days 1, 2 and 3; on day 1, 15/
268 subjects in the chloroquine arm had pruritus com-
pared to 2/266 in the dihydroartemisinin-piperaquine
arm (p = 0.002, relative risk 7.44, 95% CI 1.71-32.3), con-
sistent with the known side-effects of chloroquine. None
of the other signs or symptoms documented in the first
three days of treatment were found to be significantly dif-
ferent between the groups. There were no significant dif-
Table 1: Baseline characteristics of enrolled patients.
Characteristic Treatment arm
Number of patients 
randomized
CQ (n = 268) DP (n = 268) P
Gender: Male/Female (ratio) 126/142 (0.89) 132/136 (0.97) 0.60
Age, median years (range) 11 (0.25 -71) 12 (1 - 70) 0.38
Age Groups: 0.18
<5 years 43 (16.0) 30 (11.2)
5 -14 years 130 (48.5) 128 (47.8)
>14 years 95 (35.5) 110 (41.0)
Location: 0.61
Jalalabad 154 (57.5) 160 (59.7)
Taloqan 58 (21.6) 61 (22.8)
Maimana 56 (20.9) 47 (17.5)
Weight, median kg (range) 30 (5-93) 33 (7-89) 0.69
Geometric mean 
parasitaemia/μL (95% CI)
3339 (3000-3716) 3236 (2940 -3560) 0.67
Number with gametocytes 218 (81.3) 203 (75.2) 0.12
Haemoglobin concentration, 
mean g/dl (SD)
10.9 (1.46) 10.9 (1.42) 0.99
Anaemia (haemoglobin 
concentration < 10 g/dl)
49 (18.4) 44 (16.5) 0.35
Median white blood cells 
×109/ml, median (range)
6.0 (3.6-54) 6.6 (3.0-12.4) 0.02
Body temperature °C, mean 
(95% CI)
37.3 (37.2-37.4) 37.3 (37.2-37.4) 0.77
Median systolic blood 
pressure, mmHg (range)
100 (80-160) 100 (80-170) 0.43
Median diastolic blood 
pressure, mmHg (range)
70 (50-100) 70 (50-100) 0.38
Median pulse rate, beat/min 
(range)
88 (60-140) 88 (60-140) 0.53
Jaundice 30 (11.3) 32 (12.1) 0.79
History of convulsions in last 
24 hours
1 (0.37) 1 (0.37)
Data for chloroquine (CQ) and dihydroartemisinin-piperaquine (DP) are number (%) unless otherwise indicated.Awab et al. Malaria Journal 2010, 9:105
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ferences between the two arms in haemoglobin
concentration or occurrence of anaemia (haemoglobin <
10 g/dl) at any stage during follow-up (all p > 0.5).
Predictors of treatment failure
A univariate analysis undertaken to identify variables
associated with failure showed that treatment allocation
(chloroquine rather than dihydroartemisinin-piper-
aquine), study site (recruitment in Maimana compared to
Jalalabad), younger age and lower haemoglobin concen-
tration at baseline were all significantly associated with
recurrent infection. Admission parasitaemia, presence of
gametocytes at admission and gender had no effect in this
model (Table 2).
Multivariate analysis of the same seven variables
entered into the univariate analysis indicated that treat-
ment with chloroquine and lower haemoglobin concen-
tration at baseline were the only two significant
independent predictors of recurrent infection (Adjusted
Hazard Ratio (AHR) 3.66, 95% CI 1.48-9.02, p < 0.001 for
treatment allocation and AHR 0.50, 95% CI 0.37-0.66, p =
0.005 for haemoglobin concentration).
Discussion
This trial in three separate malaria areas of Afghanistan
confirmed that both chloroquine and dihydroartemisi-
nin-piperaquine are well-tolerated and broadly effica-
cious treatments for vivax malaria. Initial parasite
clearance was significantly faster after dihydroartemisi-
nin-piperaquine, consistent with the pharmacodynamic
properties of artemisinin-containing therapies observed
in P. falciparum [28] and P. vivax [9,24]. Nevertheless 97%
of patients in the chloroquine arm were parasite free and
afebrile by day 2, and there were no recurrences in either
arm before day 28, suggesting that P. vivax remains sensi-
tive to chloroquine in the study area, which included
locations both north and south of the Hindu Kush divide
of central Afghanistan. These data extend the geographic
range of efficacy monitoring beyond Eastern Afghanistan
where chloroquine has been shown previously to be effi-
cacious in clearing P. vivax parasitaemia [9,10]. These
findings stand in marked contrast to data from Indonesia
where P. vivax chloroquine-resistance manifests as fre-
quent failure to clear parasites by day 4 [6,29-31] and
recurrence rates by day 28 approximate 50% [29-31] or
higher [6].
Over the 56-day follow-up period dihydroartemisinin-
piperaquine proved superior to chloroquine in terms of
the prespecified survival analysis of recurrence rates.
Approximately 9% of cases had recurrent P. vivax infec-
tions in the chloroquine arm, compared to 3% in the dihy-
droartemisinin-piperaquine arm, with all failures
occurring on or after day 35. Recurrences of P. vivax may
consist of a mixture of relapses from liver hypnozoites,
recrudescences of the erythrocytic infection (due to inad-
e q u a t e  d r u g  l e v e l s  o r  r e s i s t a n c e ) ,  a n d  r e i n f e c t i o n s
acquired from additional innoculations. It is not possible
with current methodologies to distinguish reliably
between these possibilities [32,33]. However, in studies
undertaken in a neighbouring region of Pakistan, radical
treatment with primaquine following chloroquine pre-
vented the majority of recurrent infections over the
course of 9-12 months, indicating that most recurrences
following chloroquine monotherapy are likely to be
relapses from liver hypnozoites [34-36]. In this study, pri-
maquine was not given, and none of the treatments
administered has activity against P. vivax hypnozoites.
The rapid clearance of parasites in the chloroquine group,
and the fact that failures were not seen before day 28, sug-
gest that recrudescences associated with chloroquine-
resistance did not contribute significantly to the number
Figure 2 Survival curves. The proportion of subjects free from recur-
rence of P. vivax is displayed according to treatment arm; dihydroar-
temisinin-piperaquine (DP) and chloroquine (CQ).
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Figure 3 Analysis of primary outcome (cumulative failure rate at 
day 56). Non-inferiority analysis refers to the pre-specified survival 
analysis.
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of recurrences. For these reasons, the majority of recur-
r e n c e s  o b s e r v e d  i n  t h i s  s t u d y  a r e  l i k e l y  t o  h a v e  b e e n
relapses.
The pattern of recurrences is consistent with the
known properties of the drugs under study. Chloroquine
is effective in preventing early relapses (<28 days) of vivax
malaria in chloroquine-sensitive vivax malaria [4,9,10,36-
39]. This is because chloroquine is eliminated very slowly
(terminal half-life one to two months), and provides post-
treatment prophylaxis against relapse for 3-4 weeks after
treatment [39]. Piperaquine also has a very long terminal
elimination half- [40]. In an area where chloroquine-
resistant P. vivax is prevalent DHA-PPQ has been shown
in several comparative trials to prevent recurrences of P.
vivax over a six-week period more effectively than ACT
containing partner drugs with shorter half-lives [5,14,15].
In these studies, the recurrence rate (typically measured
over 42 days) can be correlated with the half-life of the
partner drug; for example, recurrences are fewer in
patients treated with dihydroartemisinin-piperaquine
compared to artemether-lumefantrine [5,14] and artesu-
nate-amodiaquine [15], presumably because the lumefan-
trine and amodiaquine components have shorter
terminal elimination half-lives (approximately 10 and 18
days respectively) than piperaquine.
In the only previous trial directly comparing dihydroar-
temisinin-piperaquine to chloroquine (combined with
sulfadoxine-pyrimethamine, CQ-SP) for P. vivax infec-
tion in Papua New Guinea, high levels of chloroquine-
resistance were present, as evidenced by prolonged para-
site clearance times in the CQ-SP arm. There was an 87%
rate of recurrence in the first 42 days after CQ-SP com-
pared to 30.6% in the dihydroartemisinin-piperaquine
arm [5], a difference that is likely to reflect both failure to
clear initial parasitaemia (leading to recrudescence) as
well as failure to suppress relapse. This study provides the
Figure 4 Proportion with clearance of parasites (a) and fever (b) at day 1-3 after treatment.
Table 2: Univariate analysis of risk factors for treatment failure
Univariate analysis
Factor Hazard Ratio p value
Chloroquine treatment 3.28 (1.41-7.63) 0.006
Female 0.93 (0.46-1.91) 0.85
Age (years) 0.96 (0.92-1.00) 0.03
Recruitment site
(Jalalabad as reference)
Taloqan 0.79 (0.26-2.43) 0.68
Maimana 3.06 (1.42-6.61) 0.004
Parasitaemia 0.86 (0.32-2.29) 0.76
Presence of gametocytes 1.13 (0.46-2.77) 0.784
Haemoglobin at admission (g/dl) 0.49 (0.37-0.65) <0.001Awab et al. Malaria Journal 2010, 9:105
http://www.malariajournal.com/content/9/1/105
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first comparison of chloroquine and dihydroartemisinin-
piperaquine in chloroquine-sensitive P. vivax, and con-
firms the longer lasting post-treatment prophylactic
effect of dihydroartemisinin-piperaquine compared to
chloroquine in this setting. The observed proportion of
chloroquine-treated patients with recurrence over 56
days is less than in a study undertaken in the Jalalabad
Malaria Reference Centre in 2004 [9] (where more than
40% of patients treated with chloroquine had recurrence
from days 28-42 after treatment), for reasons that are
unclear. Ancillary studies would help to shed further light
on these issues, including pharmacological assessment of
chloroquine and piperaquine levels in blood during the
follow-up period. This would also allow the question of
chloroquine resistance to be excluded more definitively.
This study was not powered to undertake detailed
assessments of factors associated with recurrence. In the
univariate analysis (although not the multivariate),
younger age was found to be a risk factor for recurrence, a
finding consistent with previous studies examining this
effect over longer follow-up periods [35,37]. Possible
explanations for this include pharmacokinetic effects
[39,41], reduced immunity compared to adults and
higher burdens of hypnozoites. Patients recruited in
Maimana had a significantly higher rate of failure than
those from Jalalabad in the univariate analysis although
the effect disappeared in the multivariate analysis, sug-
gesting that other factors may have contributed to this
finding. The data do not provide substantive support for
the existence of chloroquine resistance at Maimana or
any of the study sites. The finding of a strong association
between lower baseline haemoglobin and recurrence of P.
vivax infection was not anticipated and requires further
investigation.
It is possible that the action of dihydroartemisinin-pip-
e r a q u i n e  i s  s i m p l y  t o  d e l a y  r e l a p s e s  o f  v i v a x  m a l a r i a
rather than prevent them; in other words the survival
curves for recurrence with dihydroartemisinin-piper-
aquine and chloroquine will eventually merge. Studies
with longer-term follow-up would be needed to deter-
mine if this is the case and if dihydroartemisinin-piper-
aquine offers tangible benefits in terms of long-term
health of the individual (preventing relapse and associ-
ated anaemia) and possibly the community (by reducing
transmission). Any health benefits have to be balanced
against the relative cost of each treatment course, which
is currently in favour of chloroquine use. These issues
also have to be considered in the context of the challenges
of treating patients with radical therapy in this region
[35,36].
Conclusion
Both dihydroartemisinin-piperaquine and chloroquine
are efficacious treatments for P. vivax malaria across
three regions of Afghanistan. Consistent with the known
pharmacological properties of the drugs, dihydroar-
temisinin-piperaquine provides a longer period of post-
treatment prophylaxis, reducing the incidence of recur-
rence from 4-8 weeks after treatment.
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